Last edition
News about "Ouro Medicines"
Gilead Sciences to Acquire Ouro Medicines in USD 2 Billion Deal to Strengthen Immunology Pipeline
Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a deal valued at over USD 2 billion, marking a strategic move to expand its immunology and inflammation pipeline.
Ouro Medicines | 24/03/2026 | By Darshana
Ouro Medicines Receives US FDA ODD for Gamgertamig (OM336) for Immune Thrombocytopenia
Ouro Medicines has secured a second ODD from the FDA for gamgertamig (OM336), this time for immune thrombocytopenia (ITP), following an earlier designation for autoimmune hemolytic anemia (AIHA). It comes as the company completes dosing in the first cohort of its global basket trial in autoimmune cytopenias.
Ouro Medicines | 09/12/2025 | By Akanki | 239
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy